Effects of Continuous Perioperative Esketamine Infusion on Postoperative Depression in Breast Cancer Patients: A Randomized Controlled Double-Blind Trial
Open Access
- 1 October 2025
- journal article
- clinical trial-report
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 9685-9695
Abstract
Background: Comorbid depressive symptoms are prevalent in patients with breast cancer, which adversely impacts postoperative recovery outcomes. Esketamine has emerged as a promising intervention for perioperative depression due to its rapid and sustained effects. This study aims to investigate the impact of the continuous intravenous infusion of esketamine during the perioperative period on postoperative depressive symptoms in breast cancer patients. Methods: In this randomized, double-blind, controlled trial, 96 female patients aged 18– 65 years undergoing unilateral modified radical mastectomy were enrolled. Participants were randomly assigned to one of two groups. The esketamine group received 0.5 mg/kg and 0.25 mg/kg/h esketamine and the normal saline group received 5 mL and 0.25 mL/kg/h normal saline during anesthesia induction and maintenance, respectively. The primary outcome was the Hamilton Depression Rating Scale (HAMD-17) score on postoperative day 30 (POD-30). Secondary outcomes included HAMD-17 scores on POD 1 and 3; self-Rating Depression Scale (SDS) scores on POD 1, 3, and 30; serum levels of brain-derived neurotrophic factor (BDNF) and serotonin (5-hydroxytryptamine, 5-HT) after surgery; relative changes in heart rate (HR) and mean arterial pressure (MAP) before and after intubation; time to awakening; Visual Analog Scale (VAS) pain scores; and adverse events related to esketamine. Results: The HAMD-17 score on POD-30 was significantly lower in the esketamine group [3.00 (2.08– 4.10)] than in the normal saline group [5.00 (4.00– 6.20)]. Regarding secondary outcomes, HAMD-17 scores on POD 1 and 3 were significantly lower in the esketamine group. SDS scores on POD 1, 3, and 30 were also significantly lower in the esketamine group. Compared with the saline group, the esketamine group exhibited significantly higher postoperative levels of BDNF and serotonin. Additionally, VAS scores at 30 minutes after extubation were significantly lower in the esketamine group. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: Perioperative continuous administration of esketamine reduces postoperative depression scores in patients undergoing breast cancer surgery. Trial Registration: Chinese Clinical Trial Registry. Identifier: ChiCTR2200061575.Keywords
This publication has 28 references indexed in Scilit:
- Esketamine in depression: putative biomarkers from clinical researchEuropean Archives of Psychiatry and Clinical Neuroscience, 2024
- The impact of perioperative ketamine or esketamine on the subjective quality of recovery after surgery: a meta-analysis of randomised controlled trialsBritish Journal of Anaesthesia, 2024
- Effects of esketamine on postoperative negative emotions and early cognitive disorders in patients undergoing non-cardiac thoracic surgery: A randomized controlled trialJournal of Clinical Anesthesia, 2024
- The role of serotonin neurotransmission in rapid antidepressant actionsPsychopharmacology, 2022
- Intranasal esketamine: From origins to future implications in treatment-resistant depressionJournal of Psychiatric Research, 2021
- Cancer statistics for the year 2020: An overviewInternational Journal of Cancer, 2021
- Perioperative intravenous S-ketamine for acute postoperative pain in adults: A systematic review and meta-analysisJournal of Clinical Anesthesia, 2021
- Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical ReviewCNS Drugs, 2018
- Considerations on the Off-label Use of Ketamine as a Treatment for Mood DisordersJAMA, 2017
- Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled StudyBiological Psychiatry, 2016